Product Description
Artefenomel, a novel trioxolane, is a front-runner candidate for inclusion in a new antimalarial combination with ferroquine. (Sourced from: https://www.mmv.org/related-story-type/artefenomel)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Malaria, Falciparum
Phase 2: Malaria, Falciparum|Malaria|Malaria, Vivax
Phase 1: Malaria|Malaria, Vivax|Malaria, Falciparum|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACT14655 | P2 |
Completed |
Malaria, Falciparum |
2019-11-06 |
|
| FALCI | P2 |
Terminated |
Malaria, Falciparum |
2019-09-23 |
|
| QP17C19 | P1 |
Completed |
Malaria |
2019-04-19 |
|
| MMV_OZ439_16_01 | P1 |
Completed |
Malaria |
2017-05-30 |